Inflammatory Bowel Disease · Article 147

When Should CMV Colitis Be Suspected in Ulcerative Colitis?

CMV colitis UC requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

CMV colitis UC clinical reference — Related free clinical resource: First Principles of Gastroenterology and Hepatology.

CMV colitis UC: practical clinical approach

This page focuses on CMV colitis UC with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for CMV colitis UC

Clinical takeaway: For CMV colitis UC, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: CMV colitis should be considered particularly in severe or steroid-refractory ulcerative colitis, especially when symptoms fail to improve despite appropriate therapy. Diagnosis relies on colonic biopsies—preferably from inflamed or ulcerated mucosa—with histology and immunohistochemistry; blood testing alone is insufficient to exclude tissue-invasive disease. Clinically significant CMV colitis is generally treated with antiviral therapy, usually ganciclovir/valganciclovir, alongside coordinated IBD management.

Who is at risk

Severe inflammation, corticosteroid exposure and immunosuppression increase the probability of CMV reactivation in colonic tissue.

Biopsy is central

CMV inclusions can be sparse. Immunohistochemistry improves detection, and sampling ulcer bases/edges may increase yield.

Interpret positivity clinically

Low-level tissue detection does not always mean CMV is driving disease. The burden of CMV, ulceration and steroid-refractory clinical course influence the treatment decision.

Practical clinical algorithm

1. Suspect CMV in severe or steroid-refractory UC.

2. Perform flexible sigmoidoscopy/colonoscopy with targeted biopsies.

3. Use histology plus CMV immunohistochemistry; add tissue PCR selectively.

4. Treat clinically significant tissue-invasive CMV with antivirals.

5. Reassess IBD therapy and surgical risk in parallel.

Common mistakes to avoid

Using blood CMV PCR alone to exclude colitis.
Taking too few biopsies.
Treating every low-level CMV signal identically.
Delaying colectomy in a deteriorating patient while waiting for antiviral response.
Ignoring concomitant C. difficile.

Trainee takeaway

CMV matters most when severe UC is not behaving as expected; tissue diagnosis is the key to separating incidental reactivation from clinically important colitis.

Frequently asked questions

Can CMV occur in immunocompetent patients?

Yes, but clinically significant CMV colitis is far more common in severe/inflammatory or immunosuppressed contexts.

Is a blood CMV PCR enough?

No. Tissue-based diagnosis is more important for colitis.

Does antiviral therapy replace UC treatment?

No. Both infection and inflammatory disease require management.

References

1. Thomson ABR. Practice Review in Gastroenterology. CAPstone Academic Publishers; 2014.

2. Thomson ABR. Guideline-Based Management in Gastroenterology. CAPstone Academic Publishers; 2015.

3. Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. Am J Gastroenterol. 2025;120:1187-1224.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions